



August 26, 2013

Semmelweis University


The 20th Budapest Nephrology School

Methylglyoxal: a New Target in CKD

Division of Nephrology, Endocrinology and Vascular Medicine
Department of Medicine, Tohoku University School of Medicine

Sadayoshi Ito


MGO, ADMA, Oxidative Stress



LCT: lactate
GLO: Glyoxalase

DDAH: Dimethylarginine dimethylaminohydrolase
CTL: Citrulline
AMN: Amines

Methylglyoxal (MGO)




MGO is a very reactive aldehyde-deliverative involved in many biological processes such as AGE formation, glycation-methylation of DNA, transcriptional factors, etc

CKD (GFR<45ml/min/1.73m²)

- Vascular injuries (heart, brain , kidney, eye)
- Inflammations, Oxidative stress
- Insulin resistance
- Salt sensitive hypertension
- Immune dysfunctions
- Anemia (shortened life span, EPO)
- Cognitive dysfunction

MGO may play important roles in pathophysiology




CKD and plasma MGO



(Nakayama K, Am J Nephrol 28(6), 871-878, 2008)


MGO is a very reactive substance

A new radical is produced by reacting with H₂O₂





(Nakayama M, et al. Redox Rep 12; 125-133, 2007)


Metabolic pathways of MGO




REAL-TIME FLUORESCENT MICROSCOPY




MGO increases ROS in endothelial cells





(Miyazawa N, et al. Free Radic Res 44:101-107.2010.)




Metabolic Pathways of MGO: DM (Hypothesis)



Microperfusion of mTAL ~measurement of Mit ROS~



Metabolic Pathways of MGO: DM (Hypothesis)



RARP: poly(ADP-ribose) polymerase-1


(Price CL, et al: Trends in Endocrinology and Metabolism 20(7); 312-317, 2009)

MGO causes

MGO is elevated in CKD


- Vascular injuries (heart, brain , kidney, eye)
- Inflammations, Oxidative stress
- Insulin resistance?
- Salt sensitive hypertension
- Immune dysfunctions
- Anemia (shortened life span)
- Cognitive dysfunction

MGO enhances salt sensitivity of BP in SD rats



(Guo Q, et al; J Hypertension 27; 1664-1671, 2009)


MGO increases ROS in the kidney



(Guo Q, et al; J Hypertension 27; 1664-1671, 2009)

MGO decreases insulin sensitivity (M value: insulin sensitivity)

Glucose clamp in conscious rats





(Guo Q, et al; J Hypertension 27; 1664-1671, 2009)

Dahl salt-sensitive rats




H_2O_2 is high even under low Na

H_2O_2 reacts with MGO

MGO increases BP in Dhal S fed low Na



ARB improved MGO-induced damages



* $p < 0.05$ vs. MGO group

Chen. Hypertension Res: 2013 ;36:361-7

Markers of oxidative stress and inflammation in the kidney


Control

MGO-12w


MGO-4W

MGO-CAND


OPN




ED-1




CEL



8-OHdG



RAGE




Collagen deposition and perivascular fibrosis in the heart

Control


MGO-12w

MGO-4W

MGO-CAND



Pyridoxamine reduced albuminuria in Thy-1 nephritis



* $P < 0.05$ vs CON,
† $P < 0.05$ vs GN

*Original Article***Polymorphonuclear leukocyte injury by methylglyoxal and hydrogen peroxide: a possible pathological role for enhanced oxidative stress in chronic kidney disease**

Masaaki Nakayama¹, Keisuke Nakayama¹, Wan-Jun Zhu¹, Yuko Shiota², Hiroyuki Terawaki¹, Toshinobu Sato², Masahiro Kohno³ and Sadayoshi Ito^{1,2}

¹Research Division of Dialysis and Chronic Kidney Disease, Tohoku University Graduate School of Medicine, ²Department of Blood Purification, Tohoku University Hospital and ³Tohoku University, New Industry Creation Hatchery Center, Life Particle Interaction Engineering Creation, Sendai, Japan

Abstract

pathology may be linked to enhanced oxidative stress in

- Cognitive dysfunction


MGO and Brain (Pubmed 116)

- Cognitive dysfunction in DM
Brain Res. 21;1469:82-91.2012
- Alzheimer: high MGO in spinal fluid:
(Ann N Y Acad Sci 1043; 211-216, 2005)
- MGO causes β -amyloid misfolding:
(J Alzheimers Dis.30;63-73,2012. Neurochem 99; 1413-1424, 2006)
- MGO causes hippocampus damages:
(Brain Research 1006; 157-167, 2004;Intern J Biochem & Cell Biol 40; 245-257, 2008)
- MGO-producing semicarbazase-sensitive amine oxidase (SSAO) is high in serum and blood vessels in Alzheimer:
(Neurosci Lett 321; 121-21, 2002:Neurosci Lett 384; 183-187, 2005)
- GLO-1 abnormality in some nervous diseases:
(Neurosci Lett 438; 196-199, 2008)

Is it relevant in human?

ARB decreases ACR via inhibition of ROS

Ang II increase ROS via AT1R




Baseline MGO and parameters

(Ogawa S, et al Hypertension 56: 471-476, 2010)

		R ²	r	p
3-DG	$y = 0.7357x + 281.16$	0.0365	0.191135254	< 0.05
Age	$y = 0.0215x + 53.484$	0.0063	0.079234755	n.s.
BMI	$y = 0.0164x + 18.46$	0.0405	0.20127173	< 0.05
SBP	$y = 0.1037x + 101.11$	0.0689	0.262565616	< 0.05
DBP	$y = 0.0757x + 51.137$	0.0891	0.298531428	< 0.05
HbA1c	$y = -0.0002x + 6.8907$	0.0000	-0.008184052	n.s.
creatinine	$y = 0.0027x - 0.0461$	0.0609	0.246790167	< 0.05
triglyceride	$y = 0.4506x - 45.526$	0.0838	0.289456466	< 0.05
T-cholesterol	$y = 0.0895x + 152.12$	0.022	0.148330033	0.096
HDL-C	$y = -0.0089x + 56.015$	0.001	-0.031056239	n.s.
ACR	$y = -0.551x + 573.22$	0.0018	-0.042905141	n.s.
IV-collagen	$y = 0.006x + 3.3888$	0.0087	0.093111815	0.080
pentosidine	$y = 0.0283x + 38.455$	0.0043	0.065476601	n.s.
8-OHdG	$y = 0.0073x + 6.2963$	0.0084	0.091913814	n.s.
8-epi-PGF	$y = 0.3498x + 124.99$	0.0158	0.125555919	0.062
Interleukin-6	$y = -0.0022x + 2.3692$	0.0011	-0.033323818	n.s.
Interleukin-18	$y = -0.2737x + 372.95$	0.0145	-0.120536309	n.s.
MCP-1	$y = 0.2858x + 80.497$	0.0347	0.186396425	0.052
hsCRP	$y = 0.0006x - 0.051$	0.0187	0.136734098	0.074
max IMT	$y = 0.0029x + 0.4511$	0.0283	0.168266674	0.054
PWV	$y = 1.2589x + 1264.3$	0.0305	0.174520132	0.053
ABI	$y = 0.0003x + 1.0072$	0.0191	0.13802653	0.077
VEGF	$y = -0.0065x + 62.594$	0.0000	-0.006709274	n.s.
Adiponectin	$y = 0.0033x + 11.8$	0.0003	0.016928384	n.s.
TNF α	$y = 0.0046x + 0.0644$	0.0178	0.13359534	0.084
ANP	$y = -0.1346x + 93.385$	0.0051	-0.071356329	n.s.
BNP	$y = 0.0296x + 42.067$	0.0005	0.021565371	n.s.


Plasma MGO and parameters after 5 years

IMT of Carotid



Plasma MGO levels at baseline (nM)

PWV




Plasma MGO levels at baseline (nM)

(Ogawa S, et al Hypertension 2010. 56: 471-476)


Plasma MGO and parameters after 5 years

Changes in BP



Plasma MGO levels at baseline (nM)


Changes in GFR



Plasma MGO levels at baseline (nM)

(Ogawa S, et al Hypertension 2010. 56: 471-476)


MGO, ADMA, Oxidative Stress



LCT: lactate
GLO: Glyoxalase

DDAH: Dimethylarginine dimethylaminohydrolase
CTL: Citrulline
AMN: Amines


Stress responses by Nrf2 and KEAP1



ARE: antioxidant response element

Nucleus


MGO, ADMA, Oxidative Stress: advanced DN



LCT: lactate
GLO: Glyoxalase

DDAH: Dimethylarginine dimethylaminohydrolase
CTL: Citrulline
AMN: Amines


MGO, ADMA and ROS: advanced DN



LCT: lactate
GLO: Glyoxalase

DDAH: Dimethylarginine dimethylaminohydrolase
CTL: Citrulline
AMN: Amines

Changes in GFR



No. at Risk

Placebo	57	56	55	53	54	54	54	53	53	52	53	51	53	52
Bardoxolone methyl, 25mg	57	53	52	52	52	51	51	49	49	47	48	48	48	48
Bardoxolone methyl, 75mg	57	55	51	51	53	52	52	51	48	50	50	48	48	48
Bardoxolone methyl, 150mg	56	55	55	54	53	52	52	48	48	47	47	46	46	44

(Pergola PE, et al: N Engl J Med 365; 327-336, 2011)

Ongoing

~Inhibition of MGO at right phases~

- Oral pyridoxamine on peritoneal fluid MGO level in CAPD patients
- Oral pyridoxamine in schizophrenia
- Oral pyridoxamine in CKD patients



Tohoku University

~since 1907~

Thank you for your attention

100 year anniversary

